Effects of 24-Week Treatment with Acarbose on Glucagon-Like Peptide 1 in Newly Diagnosed Type 2 Diabetic Patients: a Preliminary Report

Miao-yan Zheng,Ju-hong Yang,Chun-yan Shan,Hong-tao Zhou,Yan-guang Xu,Ying Wang,Hui-zhu Ren,Bao-cheng Chang,Li-ming Chen
DOI: https://doi.org/10.1186/1475-2840-12-73
IF: 8.949
2013-01-01
Cardiovascular Diabetology
Abstract:Treatment with the alpha-glucosidase inhibitor (AGI) acarbose is associated with a significant reduction the risk of cardiovascular events. However, the underlying mechanisms of this effect are unclear. AGIs were recently suggested to participate in stimulating glucagon-like peptide 1 (GLP-1) secretion. We therefore examined the effects of a 24-week treatment of acarbose on endogenous GLP-1, nitric oxide (NO) levels, nitric oxide synthase (NOS) activity, and carotid intima-media thickness (CIMT) in newly diagnosed patients with type 2 diabetes (T2D).
What problem does this paper attempt to address?